Viatris Appoints Matthew J. Maletta as Chief Legal Officer
Rhea-AI Summary
Viatris (Nasdaq: VTRS) appointed Matthew J. Maletta as Chief Legal Officer, effective February 9, 2026, with outgoing CLO Brian Roman remaining as advisor through April 1, 2026.
Maletta brings nearly 30 years of legal experience in branded and generic pharmaceuticals, including leadership roles at Endo and Allergan and involvement in a $70 billion Allergan transaction.
Positive
- Appointed an experienced CLO with nearly 30 years of legal experience
- New CLO led major corporate transactions including the $70 billion Allergan sale
- Outgoing CLO will remain through April 1, 2026 to support transition
Negative
- Departure of a long-tenured CLO after 20+ years of service
- Leadership transition completed within a defined, short window ending April 1, 2026
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 15 | Risk tool launch | Positive | -2.4% | Launch of Aon Resilience Quotient risk and resilience analytics framework. |
| Jan 08 | Leadership appointment | Positive | +1.1% | Appointment of Lara Ramsburg to combined people and corporate affairs role. |
| Dec 18 | Pipeline milestones | Positive | +2.0% | Multiple FDA and PMDA regulatory milestones across key therapeutic franchises. |
| Dec 17 | Conference presentation | Positive | +2.1% | Upcoming presentation at the 44th J.P. Morgan Healthcare Conference. |
| Nov 24 | Investor conferences | Neutral | +1.1% | Participation in two early-December 2025 healthcare investor conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent VTRS headlines, especially governance and pipeline updates, have more often seen modest positive price alignment, with only one notable divergence on a broadly positive news item.
Over the past several months, VTRS has reported a series of mostly constructive developments. Governance and leadership updates, such as the appointment of a new Chief People and Corporate Affairs Officer on Jan. 8, 2026, saw modest gains. Pipeline and regulatory milestones announced on Dec. 18, 2025 also coincided with a positive reaction. Conference participation updates in late 2025 similarly aligned with small advances. Against this backdrop, today’s CLO appointment fits into an ongoing governance-refresh and execution narrative.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period
Maletta is an accomplished public company executive, with nearly 30 years of legal experience and deep expertise in leading legal teams for both generic and branded pharmaceutical companies. From 2015 to 2025, he served as Executive Vice President, Chief Legal Officer and Corporate Secretary at Endo, where he oversaw Endo's merger with Mallinckrodt and the subsequent spin-off of Par Health.
Prior to that, he served for over a decade in the legal department at Allergan, rising to Vice President, Associate General Counsel and Corporate Secretary. His experience at Allergan included serving as lead attorney for all business development transactions, including the
Maletta earned both his bachelor's degree in political science and his law degree from the University of Minnesota.
"First, on behalf of the Board of Directors and our entire company, I want to thank Brian Roman for his many years of dedicated leadership and service to our company," said Scott A. Smith, Viatris CEO. "His legal expertise played an important role in helping to build the company we are today. We wish him nothing but the best."
Smith continued, "With Brian's transition, we are excited to welcome Matt to what I believe is one of the strongest internal legal and compliance teams in our industry. Given his significant industry, public company and business development experience, I look forward to partnering closely with him as we continue to transform our company and pursue long-term growth."
"This is a unique opportunity to join Viatris at an exciting time in its journey," Maletta said. "I am honored to join the company and be part of an extraordinary team that makes a real difference each and every day. I look forward to the future we will be able to build together."
Roman said, "I have had so many tremendous experiences during my more than 20 years at Mylan and Viatris. I am proud of all that we have accomplished together across the multiple functions I have had the opportunity to lead during my time here. I sincerely thank our immensely talented internal legal and compliance teams for their partnership and consistent execution. We have accomplished much together, and I look forward to working with Matt during this transition phase to ensure their important work continues."
About Viatris
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the
Forward-Looking Statements
This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements about continuing to transform our company and pursuing sustainable profitable growth. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-appoints-matthew-j-maletta-as-chief-legal-officer-302677575.html
SOURCE Viatris Inc.